Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-04

FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application to authorize Kisqali Femara Co-Pack, a co-packaged product combining ribociclib and letrozole for the treatment of breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FEMARA (letrozole)
  • KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB)